NewsNanotechnology for genome editing in multiple muscles
simultaneously

9th December 2021by admin0
https://nfusion-tech.com/wp-content/uploads/2021/12/nanotechnology-for-genome-editing-in-multiple-musclessimultaneously_61b2091a5a3c1.jpeg

Many intractable diseases are the result of a genetic
mutation. Genome editing technology promises to correct the
mutation and thus new treatments for patients. However, getting the
technology to the cells that need the correction remains a major
challenge. A new study led by CiRA Junior Associate Professor
Akitsu Hotta and in collaboration with Takeda Pharmaceutical
Company Limited as part of the T-CiRA Joint Research Program
reports how lipid nanoparticles provide an effective means for the
delivery to treat Duchenne muscular dystrophy (DMD) in
mice.

Leave a Reply

Your email address will not be published. Required fields are marked *

https://nfusion-tech.com/wp-content/uploads/2019/10/Logo_newfusion-footer.png
https://nfusion-tech.com/wp-content/uploads/2019/10/Logo_newfusion-footer.png
Subscribe

If you wish to receive our latest news in your email box, just subscribe to our newsletter. We won’t spam you, we promise!

    New Fusion

    The New Fusion technology is based on a phenomenon called triplet-triplet annihilation (TTA) which is a process in which two triplet excitons annihilate and produce a higher energy singlet exciton.

    Subscribe

    If you wish to receive our latest news in your email box, just subscribe to our newsletter. We won’t spam you, we promise!

      New Fusion

      The New Fusion technology is based on a phenomenon called triplet-triplet annihilation (TTA) which is a process in which two triplet excitons annihilate and produce a higher energy singlet exciton.

      Copyright @2022 New Fusion All Rights Reserved

      Designed by FallingBrick